Quantification of Histidine-Rich Protein 3 of Plasmodium falciparum

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Ahead of Print.


https://ift.tt/2GNV3EJ

Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer

Thyroid, Ahead of Print.


https://ift.tt/2qj73Ig

The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review

Helicobacter, EarlyView.


https://ift.tt/2IJseda

Long‐term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery

The Laryngoscope, EarlyView.


https://ift.tt/2v2U9CR

Retronasal olfaction in chronic rhinosinusitis

The Laryngoscope, EarlyView.


https://ift.tt/2HrRZiT

Multiple perioral homogenous blue macules

Clinical and Experimental Dermatology, EarlyView.


https://ift.tt/2GP0NlP

Current trends in the medical management of osteoradionecrosis using triple therapy

Publication date: Available online 9 April 2018
Source:British Journal of Oral and Maxillofacial Surgery
Author(s): J. Dhanda, L. Rennie, R. Shaw
Recent guidelines from the National Institute for Health and Care Excellence (NICE) have suggested that the medical management of osteoradionecrosis (ORN) of the jaws should be used in clinical trials only, and some drugs and therapeutics committees have withdrawn funds for such prescriptions. With increased scrutiny on the use of these agents, the aims of this study were to ascertain current trends in the presentation and management of ORN, with particular focus on which agents are being used.



https://ift.tt/2v0gu41